Net Income CAGR:-31.06%(TTM)
Based on reported financial statement history.
Over longer horizons, Net Income CAGR averages -7.46% over 3 years and -31.53% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Net income CAGR shows how the company's bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
GEHC Net Income CAGR Chart
GE HealthCare Technologies Inc. (GEHC)
GEHC Quarterly Net Income Growth (YoY)
Net Income growth vs the same quarter one year earlier, last 17 quarters.
GEHC Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.99B | $2.08B | +$91.00M | +4.57% | +4.57% |
| 2024 | $1.57B | $1.99B | +$425.00M | +27.10% | +27.10% |
| 2023 | $1.92B | $1.57B | $-348.00M | -18.16% | -18.16% |
| 2022 | $2.25B | $1.92B | $-331.00M | -14.73% | -14.73% |
| 2021 | $13.85B | $2.25B | $-11.60B | -83.77% | -83.77% |
| 2020 | $1.52B | $13.85B | +$12.32B | +808.53% | +808.53% |
Quarterly Net Income: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $389.00M | +111.4% | -31.0% |
| Q4 2025 | $184.00M | -58.7% | -74.4% |
| Q3 2025 | $446.00M | -8.2% | -5.3% |
| Q2 2025 | $486.00M | -13.8% | +13.6% |
| Q1 2025 | $564.00M | -21.7% | +50.8% |
| Q4 2024 | $720.00M | +52.9% | +78.7% |
| Q3 2024 | $471.00M | +10.0% | +25.6% |
| Q2 2024 | $428.00M | +14.4% | +2.4% |
| Q1 2024 | $374.00M | -7.2% | +0.5% |
| Q4 2023 | $403.00M | +7.5% | -27.3% |
| Q3 2023 | $375.00M | -10.3% | -23.2% |
| Q2 2023 | $418.00M | +12.4% | -13.8% |
| Q1 2023 | $372.00M | -32.9% | -4.4% |
| Q4 2022 | $554.00M | +13.5% | -1.8% |
| Q3 2022 | $488.00M | +0.6% | -3.2% |
| Q2 2022 | $485.00M | +24.7% | -16.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini